This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Labopharm

Stocks in this article: DDSS VNDA NVS RNN CLDX CTIC DNDN

Given that Fanapt launched in January, assume that most of the $21 million in Fanapt revenue is actually wholesaler inventory stocking and not actual patient demand for the drug.

Prescription data from IMS bears this out. A total of 2,359 total prescriptions were written for Fanapt from January through the end of March, according to IMS Health. At a price of approximately $600 per prescription, that implies Fanapt end-user sales of $1.4 million. (I don't subscribe to IMS' prescription drug data, but the Fanapt numbers were provided to me by a fund manager who does.)

Two ways of looking at this situation: If you're a Vanda/Titan bull, the $21 million in Fanapt revenue for the just-completed quarter, even though most is inventory stocking, suggests that Novartis is gearing up for heavy end-user demand and the company believes that the Fanapt launch will go well.

If you're a bear on Fanapt and these stocks, you look at the IMS data and say patient demand for the drug is weak, and therefore, the next few quarters of sales must come from inventory de-stocking. This means the $21 million in quarterly sales will be a high water mark for the drug and won't likely be reached again for quite some time.

I received an email dump of epic proportions after my dissection of the Serdaxin depression data from Rexahn Pharmaceuticals (RNN) this week. Most of the responses were the shrieking harpy variety, but not all, including Rex W. who writes, "I understand why you're focused on Serdaxin but the great thing about Rexahn is that it's working on lots of drugs. I think the stock moves higher as Rexahn gets ready to release data on its other big drug, Zoraxel for erectile dysfunction."

I have little doubt the penny stock promoters will be working overtime to move Rexahn higher in front of whatever Zoraxel data awaits, but be forewarned that Serdaxin and Zoraxel are the same drugs. The active ingredient in both is clavulanic acid, the old antibiotic-boosting agent.

I argued persuasively for why investors should look askance at the Serdaxin data in depression, so color me equally skeptical about Zoraxel in erectile dysfunction.

If and when Rexahn does provide investors with Zoraxel data, let's hope the company is more transparent than it was this week with the Serdaxin results.

3 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,856.24 +78.09 0.44%
S&P 500 2,073.80 +12.57 0.61%
NASDAQ 4,772.9150 +24.5190 0.52%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs